The influence of the gut microbiota on host physiology: In pursuit of mechanisms

Yale Journal of Biology and Medicine

Volumn 89, Issue 3, 2016, Pages 285-297

  Jones, Rheinallt M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hormesis; Intestine; Lactobacillus; Microbiome; Probiotics; Stem cell

Indexed keywords

BACTERIOCIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SHORT CHAIN FATTY ACID; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT RESPONSIVE ELEMENT; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; BODY WEIGHT; CELL PROTECTION; COMMENSAL; CYTOKINE PRODUCTION; DYSBIOSIS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FERMENTATION; GLUCONEOGENESIS; HUMAN; IMMUNOREGULATION; INTESTINE ABSORPTION; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; NONHUMAN; OBESITY; OXIDATION REDUCTION STATE; REVIEW; TYPE VI SECRETION SYSTEM; ANIMAL; BACTERIUM; IMMUNOLOGY; INTESTINE; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; STEM CELL;

ANIMALS; BACTERIA; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; PROBIOTICS; STEM CELLS;

EID: 84989332092     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Methe BA, Nelson KE, Pop M, Creasy HH, Giglio MG, Huttenhower C, et al. A framework for human microbiome research. Nature. 2012;486(7402):215-21.
2. Proctor LM. The Human Microbiome Project in 2011 and Beyond. Cell Host Microbe. 2011;10(4):287-91.
3. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, et al. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14.
4. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635-8.
5. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-Bacterial Mutualism in the Human Intestine. Science. 2005;307(5717):1915-20.
6. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136(1):65-80.
7. Blaser MJ. The microbiome revolution. J Clin Invest. 2014;124(10):4162-5.
8. Hooper LV. Epithelial cell contributions to intestinal immunity. Advances in immunology. 2015;126:129-72.
9. Neish AS, Jones RM. Redox signaling mediates symbiosis between the gut microbiota and the intestine. Gut microbes. 2014;5(2):250-3.
10. Cho I, Blaser MJ. Applications of Next Generation Sequencing The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260-70.
11. Renz H, von Mutius E, Brandtzaeg P, Cookson WO, Autenrieth IB, Haller D. Gene-environment interactions in chronic inflammatory disease. Nature immunology. 2011;12(4):273-7.
12. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014;158(4):705-21.
13. Abreu MT, Peek RM, Jr. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014;146(6):1534-46 e3.
14. Mayer EA, Padua D, Tillisch K. Altered brain-gut axis in autism: comorbidity or causative mechanisms? BioEssays: news and reviews in molecular, cellular and developmental biology. 2014;36(10):933-9.
15. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451-63.
16. Bienenstock J, Gibson G, Klaenhammer TR, Walker WA, Neish AS. New insights into probiotic mechanisms: a harvest from functional and metagenomic studies. Gut microbes. 2013;4(2):94-100.
17. Hord NG. Eukaryotic-Microbiota Crosstalk: Potential Mechanisms for Health Benefits of Prebiotics and Probiotics. Annu Rev Nutr. 2008;28(15):1-17.
18. Pineiro M, Stanton C. Probiotic bacteria: legislative frame-work-requirements to evidence basis. J Nutr. 2007;137(3 Suppl 2):850S-3S.
19. Jones RM, Mercante JW, Neish AS. Reactive oxygen production induced by the gut microbiota: pharmacotherapeutic implications. Current medicinal chemistry. 2012;19(10):1519-29.
20. Li JY, Chassaing B, Tyagi AM, Vaccaro C, Luo T, Adams J, et al. Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest. 2016;126(6):2049-63.
21. Medzhitov R, Schneider DS, Soares MP. Disease Tolerance as a Defense Strategy. Science. 2012;335(6071):936-41.
22. Brodsky IE, Medzhitov R. Targeting of immune signalling networks by bacterial pathogens. Nature Cell Biology. 2009;11(5):521-6.
23. Jones RM, Neish AS. Recognition of bacterial pathogens and mucosal immunity. Cellular microbiology. 2011;13(5):670-6.
24. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229-41.
25. Jones RM, Sloane VM, Wu H, Luo L, Kumar A, Kumar MV, et al. Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut. 2011;60(5):648-57.
26. Parkos CA. Neutrophil-Epithelial Interactions: A Double-Edged Sword. Am J Pathol. 2016;186(6):1404-16.
27. Cheng G, Lambeth JD. NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. J Biol Chem. 2004;279(6):4737-42.
28. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004;4(3):181-9.
29. Lambeth JD, Neish AS. Nox Enzymes and New Thinking on Reactive Oxygen: A Double-Edged Sword Revisited. Annu Rev Pathol. 2014;9:119-45.
30. Ogier-Denis E, Mkaddem SB, Vandewalle A. NOX enzymes and Toll-like receptor signaling. Semin Immunopathol. 2008;30(3):291-300.
31. Owusu-Ansah E, Banerjee U. Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation. Nature. 2009;461(7263):537-41.
32. Tsukagoshi H, Busch W, Benfey PN. Transcriptional regulation of ROS controls transition from proliferation to differentiation in the root. Cell. 2010;143(4):606-16.
33. Love NR, Chen Y, Ishibashi S, Kritsiligkou P, Lea R, Koh Y, et al. Amputation-induced reactive oxygen species are required for successful Xenopus tadpole tail regeneration. Nat Cell Biol. 2012;15(2):222-8.
34. Morimoto H, Iwata K, Ogonuki N, Inoue K, Atsuo O, Kanatsu-Shinohara M, et al. ROS are required for mouse spermatogonial stem cell self-renewal. Cell stem cell. 2013;12(6):774-86.
35. Jones RM, Luo L, Ardita CS, Richardson AN, Kwon YM, Mercante JW, et al. Symbiotic lactobacilli stimulate gut epithelial proliferation via Nox-mediated generation of reactive oxygen species. The EMBO journal. 2013;32(23):3017-28.
36. Alam A, Leoni G, Wentworth CC, Kwal JM, Wu H, Ardita CS, et al. Redox signaling regulates commensal-mediated mucosal homeostasis and restitution and requires formyl peptide receptor 1. Mucosal Immunol. 2014;7(3):645-55.
37. Swanson PA, II, Kumar A, Samarin S, Vijay-Kumar M, Kundu K, Murthy N, et al. Enteric commensal bacteria potentiate epithelial restitution via reactive oxygen species-mediated inactivation of focal adhesion kinase phosphatases. Proc Natl Acad Sci USA. 2011;108(21):8803-8.
38. Hernandez-Garcia D, Wood CD, Castro-Obregon S, Covar-rubias L. Reactive oxygen species: A radical role in development? Free Radic Biol Med. 2010;49(2):130-43.
39. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245-313.
40. Bedard K, Lardy B, Krause KH. NOX family NADPH oxidases: not just in mammals. Biochimie. 2007;89(9):1107-12.
41. Terada LS. Specificity in reactive oxidant signaling: think globally, act locally. J Cell Biol. 2006;174(5):615-23.
42. Barford D. The role of cysteine residues as redox-sensitive regulatory switches. Curr Opin Struct Biol. 2004;14(6):679-86.
43. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005;120(5):649-61.
44. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol. 2005;17(2):183-9.
45. Luebke JL, Giedroc DP. Cysteine Sulfur Chemistry in Transcriptional Regulators at the Host Bacterial Pathogen Interface. Biochemistry-Us. 2015;54(21):3235-49.
46. Wentworth CC, Alam A, Jones RM, Nusrat A, Neish AS. Enteric commensal bacteria induce ERK pathway signaling via formyl peptide receptor (FPR)-dependent redox modulation of Dual specific phosphatase 3 (DUSP3). J Biol Chem. 2011; 286(44):38448-55.
47. Wentworth CC, Jones RM, Kwon YM, Nusrat A, Neish AS. Commensal-Epithelial Signaling Mediated via Formyl Peptide Receptors. Am J Pathol. 2010;177(6):2782-90.
48. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell. 2005;121(5):667-70.
49. Chiarugi P, Buricchi F. Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslation modifications. Antioxid Redox Signal. 2007;9(1):1-24.
50. Kumar A, Wu H, Collier-Hyams LS, Hansen JM, Li T, Yamoah K, et al. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. The EMBO journal. 2007;26(21):4457-66.
51. Venugopal R, Jaiswal AÄ. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1‚Äâgene. Proceedings of the National Academy of Sciences. 1996;93(25):14960-5.
52. An JH, Blackwell TK. SKN-1 links C. elegans mesendodermal specification to a conserved oxidative stress response. Genes Dev. 2003;17(15):1882-93.
53. Sykiotis GP, Bohmann D. Keap1/Nrf2 Signaling Regulates Oxidative Stress Tolerance and Lifespan in Drosophila. Developmental Cell. 2008;14(1):76-85.
54. Kobayashi M, Itoh K, Suzuki T, Osanai H, Nishikawa K, Katoh Y, et al. Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system. Genes to Cells. 2002;7(8):807-20.
55. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/Small Maf Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through Antioxidant Response Elements. Biochemical and Biophysical Research Communications. 1997;236(2):313-22.
56. Motohashi H, O'Connor T, Katsuoka F, Engel JD, Yamamoto M. Integration and diversity of the regulatory net work composed of Maf and CNC families of transcription factors. Gene. 2002;294(1-2):1-12.
57. Kobayashi A, Kang M-I, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase To Regulate Proteasomal Degradation of Nrf2. Mol Cell Biol. 2004;24(16):7130-9.
58. Jones RM, Desai C, Darby TM, Luo L, Wolfarth AA, Scharer CD, et al. Lactobacilli Modulate Epithelial Cytoprotection through the Nrf2 Pathway. Cell reports. 2015;12(8):1217-25.
59. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Research. 2010;38(17):5718-34.
60. Silva-Palacios A, Konigsberg M, Zazueta C. Nrf2 signaling and redox homeostasis in the aging heart: A potential target to prevent cardiovascular diseases? Ageing research reviews. 2016;26:81-95.
61. Esteras N, Dinkova-Kostova AT, Abramov AY. Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function. Biol Chem. 2016;397(5):383-400.
62. Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, et al. The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance. Oxid Med Cell Longev. 2016;2016:1958174.
63. Ryoo IG, Lee SH, Kwak MK. Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance. Oxid Med Cell Longev. 2016;2016:2428153.
64. Leinonen HM, Kansanen E, Polonen P, Heinaniemi M, Levonen AL. Dysregulation of the Keap1-Nrf2 pathway in cancer. Biochemical Society transactions. 2015;43(4):645-9.
65. Zhang C, Shu L, Kong AT. MicroRNAs: New players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways. Current pharmacology reports. 2015;1(1):21-30.
66. Jimenez-Osorio AS, Gonzalez-Reyes S, Pedraza-Chaverri J. Natural Nrf2 activators in diabetes. Clin Chim Acta. 2015;448:182-92.
67. Schäfer M, Dütsch S, auf dem Keller U, Navid F, Schwarz A, Johnson DA, et al. Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection in the epidermis. Genes Dev. 2010;24(10):1045-58.
68. Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. Journal of AOAC International. 2012;95(1):50-60.
69. Bach Knudsen KE. Microbial degradation of whole-grain complex carbohydrates and impact on short-chain fatty acids and health. Adv Nutr. 2015;6(2):206-13.
70. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40(3):235-43.
71. Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes. 2014;4:e121.
72. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325-40.
73. Sepponen K, Ruusunen M, Pakkanen JA, Poso AR. Expression of CD147 and monocarboxylate transporters MCT1, MCT2 and MCT4 in porcine small intestine and colon. Vet J. 2007;174(1):122-8.
74. Kaji I, Iwanaga T, Watanabe M, Guth PH, Engel E, Kaunitz JD, et al. SCFA transport in rat duodenum. Am J Physiol-Gastr L. 2015;308(3):G188-G97.
75. Schroder O, Opritz J, Stein J. Substrate and inhibitor specificity of butyrate uptake in apical membrane vesicles of the rat distal colon. Digestion. 2000;62(2-3):152-8.
76. Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN. Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr. 2005;82(3):559-67.
77. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278(13):11312-9.
78. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A Is a G-protein-Coupled Receptor for the Bacterial Fermentation Product Butyrate and Functions as a Tumor Suppressor in Colon. Cancer Res. 2009;69(7):2826-32.
79. Kondo T, Kishi M, Fushimi T, Kaga T. Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation. J Agric Food Chem. 2009;57:5982-6.
80. Gao Z. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58:1509-17.
81. Kimura I. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci USA. 2011;108:8030-5.
82. De Vadder F. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156:84-96.
83. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol-Endoc M. 2006;290(3):E550-E9.
84. De Silva A, Bloom SR. Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. Gut Liver. 2012;6(1):10-20.
85. Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obesity. 2015;39(3):424-9.
86. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol-Reg I. 1999;277(3):R910-R6.
87. Schjoldager BTG, Mortensen PE, Christiansen J, Orskov C, Holst JJ. Glp-1 (Glucagon-Like Peptide-1) and Truncated Glp-1, Fragments of Human Proglucagon, Inhibit Gastric-Acid Secretion in Humans. Digest Dis Sci. 1989;34(5):703-8.
88. Wolever T, Brighenti F, Royall D, Jenkins A, Jenkins D. Effect of rectal infusion of short chain fatty acids in human subjects. Am J Gastroenterol. 1989;84:1027-33.
89. Ge H. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology. 2008;149:4519-26.
90. Grootaert C. Bacterial monocultures, propionate, butyrate and H2O2 modulate the expression, secretion and structure of the fasting induced adipose factor in gut epithelial cell lines. Environ Microbiol. 2011;13:1778-89.
91. Alex S, Lange K, Amolo T, Grinstead JS, Haakonsson AK, Szalowska E, et al. Short-Chain Fatty Acids Stimulate Angiopoietin-Like 4 Synthesis in Human Colon Adenocarcinoma Cells by Activating Peroxisome Proliferator-Activated Receptor gamma. Mol Cell Biol. 2013;33(7):1303-16.
92. Dewulf EM. Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPAR[gamma]-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem. 2011;22:712-22.
93. Samuel BS. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA. 2008;105:16767-72.
94. Demigne C. Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br J Nutr. 1995;74:209-19.
95. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9:407-16.
96. Li X. Acetic acid activates the AMP-activated protein kinase signaling pathway to regulate lipid metabolism in bovine hepatocytes. PLoS ONE. 2013;8:e67880.
97. Sakakibara S, Yamauchi T, Oshima Y, Tsukamoto Y, Kadowaki T. Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice. Biochem Biophys Res Comm. 2006;344:597-604.
98. Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS ONE. 2013;8:e63388.
99. Brown AJ. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278:11312-9.
100. Kim CH, Park J, Kim M. Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immune network. 2014;14(6):277-88.
101. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013;145:396-406.
102. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461(7268):1282-U119.
103. Smith PM. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569-73.
104. Zuniga LA, Jain R, Haines C, Cua DJ. Th17 cell development: from the cradle to the grave. Immunol Rev. 2013;252:78-88.
105. Sartor RB. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol. 2011;4:127-32.
106. Atarashi K, Honda K. Microbiota in autoimmunity and tolerance. Curr Opin Immunol. 2011;23:761-8.
107. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015;8(1):80-93.
108. Nancey S, Bienvenu J, Coffin B, Andre F, Descos L, Flourie B. Butyrate strongly inhibits in vitro stimulated release of cytokines in blood. Dig Dis Sci. 2002;47(4):921-8.
109. Cavaglieri CR, Nishiyama A, Fernandes LC, Curi R, Miles EA, Calder PC. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life sciences. 2003;73(13):1683-90.
110. Kurita-Ochiai T, Fukushima K, Ochiai K. Volatile fatty acids, metabolic by-products of periodontopathic bacteria, inhibit lymphocyte proliferation and cytokine production. Journal of dental research. 1995;74(7):1367-73.
111. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451-5.
112. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446-50.
113. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232-6.
114. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science. 2001;294(5544):1102-5.
115. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30(6):832-44.
116. Wang B, Morinobu A, Horiuchi M, Liu J, Kumagai S. Butyrate inhibits functional differentiation of human monocytederived dendritic cells. Cellular immunology. 2008;253(1-2):54-8.
117. Nascimento CR, Freire-de-Lima CG, da Silva de Oliveira A, Rumjanek FD, Rumjanek VM. The short chain fatty acid sodium butyrate regulates the induction of CD1a in developing dendritic cells. Immunobiology. 2011;216(3):275-84.
118. Berndt BE, Zhang M, Owyang SY, Cole TS, Wang TW, Luther J, et al. Butyrate increases IL-23 production by stimulated dendritic cells. Am J Physiol Gastrointest Liver Physiol. 2012;303(12):G1384-92.
119. Frikeche J, Simon T, Brissot E, Gregoire M, Gaugler B, Mohty M. Impact of valproic acid on dendritic cells function. Immunobiology. 2012;217(7):704-10.
120. Nastasi C, Candela M, Bonefeld CM, Geisler C, Hansen M, Krejsgaard T, et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Scientific reports. 2015;5:16148.
121. Atassi F, Servin AL. Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosis-associated pathogens. Fems Microbiol Lett. 2010;304(1):29-38.
122. Aldunate M, Srbinovski D, Hearps AC, Latham CF, Ram-sland PA, Gugasyan R, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Frontiers in physiology. 2015;6:164.
123. Alvarez-Sieiro P, Montalban-Lopez M, Mu D, Kuipers OP. Bacteriocins of lactic acid bacteria: extending the family. Appl Microbiol Biotechnol. 2016;100(7):2939-51.
124. Donia MS, Fischbach MA. Small molecules from the human microbiota. Science. 2015;349(6246):1254766.
125. Fischbach M. Insights from a global view of secondary metabolism: Small molecules from the human microbiota. Abstr Pap Am Chem S. 2014:248.
126. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nature reviews Microbiology. 2005;3(10):777-88.
127. Chenoll E, Casinos B, Bataller E, Astals P, Echevarria J, Iglesias JR, et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Applied and environmental microbiology. 2011;77(4):1335-43.
128. Czaran TL, Hoekstra RF, Pagie L. Chemical warfare between microbes promotes biodiversity. Proc Natl Acad Sci USA. 2002;99(2):786-90.
129. Di Cagno R, De Angelis M, Limitone A, Minervini F, Simonetti MC, Buchin S, et al. Cell-cell communication in sourdough lactic acid bacteria: A proteomic study in Lactobacillus sanfranciscensis CB1. Proteomics. 2007;7(14):2430-46.
130. Majeed H, Gillor O, Kerr B, Riley MA. Competitive interactions in Escherichia coli populations: the role of bacteriocins. Isme J. 2011;5(1):71-81.
131. Gillor O, Giladi I, Riley MA. Persistence of colicinogenic Escherichia coli in the mouse gastrointestinal tract. Bmc Microbiol. 2009;9:165.
132. Hillman JD. Genetically modified Streptococcus mutans for the prevention of dental caries. Anton Leeuw Int J G. 2002;82(1-4):361-6.
133. Dawid S, Roche AM, Weiser JN. The blp bacteriocins of Streptococcus pneumoniae mediate intraspecies competition both in vitro and in vivo. Infect Immun. 2007;75(1):443-51.
134. O'Hara AM, Shanahan F. Mechanisms of action of probiotics in intestinal diseases. TheScientificWorldJournal. 2007;7:31-46.
135. Dobson A, Cotter PD, Ross RP, Hill C. Bacteriocin production: a probiotic trait? Applied and environmental microbiology. 2012;78(1):1-6.
136. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. Bacterial competition: surviving and thriving in the microbial jungle. Nature reviews Microbiology. 2010;8(1):15-25.
137. Perez RH, Zendo T, Sonomoto K. Novel bacteriocins from lactic acid bacteria (LAB): various structures and applications. Microb Cell Fact. 2014;13 Suppl 1:S3.
138. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CGM. Bacteriocin production as a mechanism for the anti-infective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA. 2007;104(18):7617-21.
139. Messaoudi S, Manai M, Kergourlay G, Prevost H, Connil N, Chobert JM, et al. Lactobacillus salivarius: Bacteriocin and probiotic activity. Food Microbiol. 2013;36(2):296-304.
140. O'Shea EF, O'Connor PM, Raftis EJ, O'Toole PW, Stanton C, Cotter PD, et al. Production of Multiple Bacteriocins from a Single Locus by Gastrointestinal Strains of Lactobacillus salivarius. J Bacteriol. 2011;193(24):6973-82.
141. Walsh MC, Gardiner GE, Hart OM, Lawlor PG, Daly M, Lynch B, et al. Predominance of a bacteriocin-producing Lactobacillus salivarius component of a five-strain probiotic in the porcine ileum and effects on host immune phenotype. Fems Microbiol Ecol. 2008;64(2):317-27.
142. Lee JH, Karamychev VN, Kozyavkin SA, Mills D, Pavlov AR, Pavlova NV, et al. Comparative genomic analysis of the gut bacterium Bifidobacterium longum reveals loci susceptible to deletion during pure culture growth. Bmc Genomics. 2008;9:247.
143. Bhardwaj A, Gupta H, Kapila S, Kaur G, Vij S, Malik RK. Safety assessment and evaluation of probiotic potential of bacteriocinogenic Enterococcus faecium KH 24 strain under in vitro and in vivo conditions. Int J Food Microbiol. 2010;141(3):156-64.
144. Lu RL, Fasano S, Madayiputhiya N, Morin NP, Nataro J, Fasano A. Isolation, Identification, and Characterization of Small Bioactive Peptides From Lactobacillus GG Conditional Media That Exert Both Anti-Gram-negative and Gram-positive Bactericidal Activity. J Pediatr Gastr Nutr. 2009;49(1):23-30.
145. Ruas-Madiedo P, Medrano M, Salazar N, de los Reyes-Gavilan CG, Perez PF, Abraham AG. Exopolysaccharides produced by Lactobacillus and Bifidobacterium strains abrogate in vitro the cytotoxic effect of bacterial toxins on eukaryotic cells. J Appl Microbiol. 2010;109(6):2079-86.
146. Marianelli C, Cifani N, Pasquali P. Evaluation of antimicrobial activity of probiotic bacteria against Salmonella enterica subsp. enterica serovar typhimurium 1344 in a common medium under different environmental conditions. Res Microbiol. 2010;161(8):673-80.
147. Cursino L, Smajs D, Smarda J, Nardi RMD, Nicoli JR, Chartone-Souza E, et al. Exoproducts of the Escherichia coli strain H22 inhibiting some enteric pathogens both in vitro and in vivo. J Appl Microbiol. 2006;100(4):821-9.
148. Schamberger GP, Diez-Gonzalez F. Characterization of colicinogenic Escherichia coli strains inhibitory to enterohemorrhagic Escherichia coli. Journal of food protection. 2004;67(3):486-92.
149. Fujimoto S, Tomita H, Wakamatsu E, Tanimoto K, Ike Y. Physical mapping of the conjugative bacteriocin plasmid pPD1 of Enterococcus faecalis and identification of the determinant related to the pheromone response. J Bacteriol. 1995;177(19):5574-81.
150. Kommineni S, Bretl DJ, Lam V, Chakraborty R, Hayward M, Simpson P, et al. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature. 2015;526(7575):719-22.
151. Russell AB, Peterson SB, Mougous JD. Type VI secretion system effectors: poisons with a purpose. Nature Reviews Microbiology. 2014;12(2):137-48.
152. Silverman JM, Brunet YR, Cascales E, Mougous JD. Structure and Regulation of the Type VI Secretion System. Annu Rev Microbiol. 2012;66:453-72.
153. Fu Y, Waldor MK, Mekalanos JJ. Tn-Seq Analysis of Vibrio cholerae Intestinal Colonization Reveals a Role for T6SS-Mediated Antibacterial Activity in the Host. Cell Host Microbe. 2013;14(6):652-63.
154. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837-48.
155. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14.
156. Russell AB, Wexler AG, Harding BN, Whitney JC, Bohn AJ, Goo YA, et al. A Type VI Secretion-Related Pathway in Bacteroidetes Mediates Interbacterial Antagonism. Cell Host Microbe. 2014;16(2):227-36.
157. Wexler AG, Bao YQ, Whitney JC, Bobay LM, Xavier JB, Schofield WB, et al. Human symbionts inject and neutralize antibacterial toxins to persist in the gut. Proc Natl Acad Sci USA. 2016;113(13):3639-44.
158. Coyne MJ, Roelofs KG, Comstock LE. Type VI secretion systems of human gut Bacteroidales segregate into three genetic architectures, two of which are contained on mobile genetic elements. Bmc Genomics. 2016;17:58.
159. Chatzidaki-Livanis M, Geva-Zatorsky N, Comstock LE. Bacteroides fragilis type VI secretion systems use novel effector and immunity proteins to antagonize human gut Bacteroidales species. Proc Natl Acad Sci USA. 2016;113(13):3627-32.
160. Cavera VL, Arthur TD, Kashtanov D, Chikindas ML. Bacteriocins and their position in the next wave of conventional antibiotics. Int J Antimicrob Ag. 2015;46(5):494-501.
161. Nigam A, Gupta D, Sharma A. Treatment of infectious disease: Beyond antibiotics. Microbiol Res. 2014;169(9-10):643-51.
162. Al Kassaa I, Hober D, Hamze M, Chihib NE, Drider D. Antiviral Potential of Lactic Acid Bacteria and Their Bacteriocins. Probiotics Antimicro. 2014;6(3-4):177-85.
163. Kaur S, Kaur S. Bacteriocins as Potential Anticancer Agents. Front Pharmacol. 2015;6:272.